Pharmacogenetics of antiepileptic drugs: A brief review

The goal of pharmacogenetic research is to assist clinicians in predicting patient response to medications when genetic variations are identified. The pharmacogenetic variation of antiepileptic drug response and side effects has yielded findings that have been included in drug labeling and guidelines. The goal of this review is to provide a brief overview of the pharmacogenetic research on antiepileptic drugs. It will focus on findings that have been included in drug labeling, guidelines, and candidate pharmacogenetic variation. Overall, several genes have been included in guidelines by national and international organizations; however, much work is needed to implement and evaluate their use in clinical settings.

• Publication year

  2016

• Venue

  Mental Health Clinician

• Publication date

  2016-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.9740/mhc.2016.01.028PMID 29955444PMCID 6009246
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Personalized medicine approaches in epilepsy

  2015cited by this paper
• Urea Cycle Disorders Overview

  2015cited by this paper
• Sodium channels, inherited epilepsy, and antiepileptic drugs.

  2014cited by this paper
• Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy.

  2014cited by this paper
• Is There a Need to Teach Pharmacogenetics?

  2014cited by this paper
• Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA‐B Genotypes and Phenytoin Dosing

  2014cited by this paper
• Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis.

  2013cited by this paper
• HLA-A*31:01 and HLA-B*15:02 as genetic markers for carbamazepine hypersensitivity in children

  2013cited by this paper
• Lack of association between polymorphism in ABCC2 gene and response to antiepileptic drug treatment in Croatian patients with epilepsy.

  2013cited by this paper
• Defects in amino acid catabolism and the urea cycle.

  2013cited by this paper
• Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed

  2013cited by this paper
• Clinical and molecular features of POLG-related mitochondrial disease.

  2013cited by this paper
• Alpers-Huttenlocher syndrome.

  2013cited by this paper
• SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis.

  2013cited by this paper
• Suggested guidelines for the diagnosis and management of urea cycle disorders

  2012cited by this paper
• Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening Programmes

  2012cited by this paper
• Hyperammonemia in review: pathophysiology, diagnosis, and treatment

  2012cited by this paper
• Clinical application of cardiovascular pharmacogenetics.

  2012cited by this paper
• Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Carbamazepine Dosing

  2012cited by this paper
• Preparing for precision medicine.

  2012cited by this paper
• Lack of association between ABCC2 gene variants and treatment response in epilepsy.

  2012cited by this paper
• Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization.

  2012cited by this paper
• Basic mechanisms of antiepileptic drugs and their pharmacokinetic/pharmacodynamic interactions: an update

  2011cited by this paper
• Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry.

  2011cited by this paper
• HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.

  2011cited by this paper
• Pharmacogenetics: From Bench to Byte— An Update of Guidelines

  2011cited by this paper
• Kynurenic acid and kynurenine aminotransferases in retinal aging and neurodegeneration

  2011cited by this paper
• Antiepileptic drug therapy: does mechanism of action matter?

  2011cited by this paper
• New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA.

  2011cited by this paper
• Gene-wide tagging study of the association between ABCC2, ABCC5 and ABCG2 genetic polymorphisms and multidrug resistance in epilepsy.

  2011cited by this paper
• Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy

  2011cited by this paper
• Pharmacoeconomic evaluation of warfarin pharmacogenomics

  2011cited by this paper
• Antiepileptic drug therapy: does mechanism of action matter?

  2011cited by this paper
• Pharmacogenomics and epilepsy: the road ahead.

  2011cited by this paper
• Absence of a general association between ABCB1 genetic variants and response to antiepileptic drugs in epilepsy patients.

  2010cited by this paper
• Maternal EPHX1 polymorphisms and risk of phenytoin-induced congenital malformations

  2010cited by this paper
• Epilepsy pharmacogenetics.

  2009cited by this paper
• Genetic Variants in Microsomal Epoxide Hydrolase Influence Carbamazepine Dosing

  2009cited by this paper
• The clinical impact of pharmacogenetics on the treatment of epilepsy

  2009cited by this paper
• Pharmacogenetic testing in psychiatry: a review of features and clinical realities.

  2008cited by this paper
• Human leukocyte antigens and drug hypersensitivity

  2007cited by this paper
• The HLA System: Genetics, Immunology, Clinical Testing, and Clinical Implications

  2007cited by this paper
• Therapeutic Drug Monitoring and Clinical Outcomes in Epileptic Egyptian Patients: A Gene Polymorphism Perspective Study

  2007cited by this paper
• The Role of Pharmacogenetics in the Metabolism of Antiepileptic Drugs

  2007cited by this paper
• The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases.

  2006cited by this paper
• ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients.

  2006cited by this paper
• A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose

  2006cited by this paper
• Valproate‐induced hyperammonemic encephalopathy

  2006cited by this paper
• Polygenic epilepsy.

  2006cited by this paper
• Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions

  2006cited by this paper
• Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin.

  2005cited by this paper
• Genetic counseling issues in urea cycle disorders.

  2005cited by this paper
• CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population

  2005cited by this paper
• Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles.

  2005cited by this paper
• Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients

  2005cited by this paper
• Pharmacogenetics and Pharmacogenomics Instruction in Colleges and Schools of Pharmacy in the United States

  2005cited by this paper
• Genetic approach to prenatal diagnosis in urea cycle defects

  2004cited by this paper
• POLG mutations associated with Alpers' syndrome and mitochondrial DNA depletion

  2004cited by this paper
• Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future.

  2004cited by this paper
• Genetic polymorphisms of the human MDR1 drug transporter.

  2003cited by this paper
• Polymorphism in clinical immunology – From HLA typing to immunogenetic profiling

  2003cited by this paper
• Valproate-Induced Hyperammonemic Encephalopathy

  2002cited by this paper
• Effectiveness of First Antiepileptic Drug

  2001cited by this paper
• Urea cycle disorders.

  2000cited by this paper
• Early identification of refractory epilepsy.

  2000cited by this paper
• Pharmacogenetics and the practice of medicine

  2000cited by this paper
• Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes.

  2000cited by this paper
• Carnitine for valproic acid-induced hyperammonemia.

  1997cited by this paper
• Interindividual and interspecies variation in hepatic microsomal epoxide hydrolase activity: studies with cis-stilbene oxide, carbamazepine 10, 11-epoxide and naphthalene.

  1996cited by this paper
• Valproate-induced hyperammonemia of renal origin. Effects of valproate on glutamine transport in rat kidney mitochondria.

  1989cited by this paper
• Membrane Glycoproteins: A Review of Structure and Function

  1976cited by this paper
• Genome-wide association study identifies HLA-A ∗ 3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population

  year unknowncited by this paper
• SCN 1 A , SCN 2 A and SCN 3 A gene polymorphisms and responsiveness to antiepileptic drugs : a multicenter cohort study and meta

  year unknowncited by this paper

• Anti-seizure Medications: Challenges and Opportunities.

  2024cites this paper
• The potential implication of MDR1 and NAC1 genetic polymorphisms on resistance to antiepileptic drugs among a Jordanian epileptic population: a cross-sectional study

  2023influential citation
• Assessment of clinically actionable pharmacogenetic markers to stratify anti-seizure medications

  2023cites this paper
• SCN1A polymorphisms influence the antiepileptic drugs responsiveness in Jordanian epileptic patients

  2022cites this paper
• ABCG2, SCN1A and CYP3A5 genes polymorphism and drug-resistant epilepsy in children: A case-control study.

  2022cites this paper
• The possible effect of sCn1a and sCn2a genetic variants on carbamazepine response among Khyber Pakhtunkhwa epileptic patients, Pakistan

  2018cites this paper
• The possible effect of SCN1A and SCN2A genetic variants on carbamazepine response among Khyber Pakhtunkhwa epileptic patients, Pakistan

  2018cites this paper
• The potential implication of SCN1A and CYP3A5 genetic variants on antiepileptic drug resistance among Egyptian epileptic children.

  2016cites this paper
• Personalized medicine approaches in epilepsy

  2015cites this paper